INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Shareholders held by INVO Bioscience, Inc. on December 26, 2023. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol "INVO".
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Shareholder Votes
Shareholders voted on three proposals at the Annual Meeting, where 952,082 shares were represented:
- Proposal 1 (Election of Directors): All five nominees were elected to the Board of Directors. Broker non-votes totaled 763,010 shares for each nominee.
- Proposal 2 (Ratification of Auditors): Shareholders approved the appointment of M&K CPAs PLLC as the independent public accountant for the fiscal year ending December 31, 2023.
- Proposal 3 (Warrant Exercise Price Reduction): Shareholders approved a reduction of the exercise price for March 2023 private placement warrants from $12.60 per share to $2.85 per share, pursuant to Nasdaq Marketplace Rule 5635(d).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the procedural details of the shareholder vote.
Key Facts for Investor Verification
- Verify the impact of the warrant exercise price reduction (from $12.60 to $2.85) on potential future dilution.
- Confirm the composition of the newly elected Board of Directors: Steven Shum, Trent Davis, Matthew Szot, Barbara Ryan, and Rebecca Messina.
- Note the significant number of broker non-votes (763,010) on the director election and warrant reduction proposals.
- Review the Definitive Proxy Statement filed on November 24, 2023, for detailed background on the proposals.